NanoZymeX is a nanobiotechnology startup developing next-generation enzyme replacement therapies using proprietary lipid-based nanoparticles. Originating from research at the University of Basel, NanoZymeX integrates nanotechnology and protein therapeutics to improve intracellular delivery, reduce immune responses, and enable targeted treatment of rare genetic diseases such as Pompe disease.